AUSTIN, Texas, Dec. 6, 2010 /PRNewswire-FirstCall/ — Following
the annual meeting of its stockholders on Friday, December 3, 2010,
Vermillion, Inc. (Nasdaq:
VRML) announced that its stockholders approved the
reappointment of Gail S. Page, John F. Hamilton and Dr. William C.
Wallen as directors of the Company. In addition, shareholders
approved the 2010 Stock Incentive Plan and ratified
PricewaterhouseCoopers LLP as its independent registered public
accounting firm.
Gail S. Page joined Vermillion in January 2004. She has
been a director since 2005 and currently holds the position of
Chief Executive Officer. In this role, she is responsible for
leading Vermillion and its development and commercialization of the
OVA1™ Test. From December 2005 to March 2009, Ms. Page
was President and Chief Executive Officer. On March 27,
2009, Gail Page was asked to step down as President and Chief
Executive Officer to conserve Vermillion’s resources due to
Vermillion’s Chapter 11 bankruptcy filing. In connection with
Vermillion’s emergence from bankruptcy, however, Ms. Page was
reappointed as Chief Executive Officer of Vermillion on February 1,
2010.
John F. Hamilton has been a member of the Board of Directors
since April 2008. He previously served as Vice President and
Chief Financial Officer of Depomed, Inc., from 1997 until his
retirement in 2007.
Dr. William C. Wallen was appointed to the Board of Directors on
February 1, 2010, and serves as Chairman of the Company’s
Nominating and Governance Committee. He is also a member of
Vermillion’s Audit Committee and Compensation Committee, and served
on its Scientific Advisory Board from April 2006 until February
2010 when he joined the Board of Directors. Dr. Wallen served
as the Senior Vice President and Chief Scientific Officer of IDEXX
Laborator
‘/>”/>
